Literature DB >> 19950406

Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: an analysis of 657 patients.

Laura C Collins1, Ninah Achacoso, Larissa Nekhlyudov, Suzanne W Fletcher, Reina Haque, Charles P Quesenberry, Balaram Puligandla, Najeeb S Alshak, Lynn C Goldstein, Allen M Gown, Stuart J Schnitt, Laurel A Habel.   

Abstract

Prior studies have shown that young patient age at diagnosis is associated with an increased risk of local recurrence among women with ductal carcinoma in situ (DCIS) treated with breast-conserving therapy. Whether this can be explained by differences in clinical or pathologic features of DCIS according to age is an unresolved issue. We compared clinical and pathologic features of DCIS among 657 women in 4 age groups: <45 years (n=111), 45 to 54 years (n=191), 55 to 64 years (n=160), and 65+ years (n=195). DCIS presented as a mammographic abnormality less often in younger than in older women (68%, 82%, 81%, and 86% for women <45, 45 to 54, 55 to 64, and 65+ y, respectively; P=0.003). Among the pathologic features analyzed, DCIS extent as determined by the number of low power fields was greater in younger than in older women (mean number of low power fields were 18.6, 14.2, 10.8, and 11.3 in women <45, 45 to 54, 55 to 64 and 65+ y; P<0.001). In addition, cancerization of lobules was present more often in younger than in older women (77%, 73%, 66%, and 50% for women <45, 45 to 54, 55 to 64 and 65+ y, respectively; P<0.0001). Of note, we found no statistically significant relationship between age and DCIS architectural pattern, nuclear grade, comedo necrosis or expression of estrogen receptor, progesterone receptor or human epidermal growth factor receptor 2. We conclude that DCIS in younger women is more often symptomatic, is more extensive, and more often shows cancerization of lobules than DCIS in older women. Whether these features contribute to the higher local recurrence risk in young women with DCIS treated with the breast-conserving therapy requires further study.

Entities:  

Mesh:

Year:  2009        PMID: 19950406      PMCID: PMC2788310          DOI: 10.1097/pas.0b013e3181b7cb7a

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  30 in total

1.  Relationship between the morphological and biological characteristics of intraductal components accompanying invasive ductal breast carcinoma and patient age.

Authors:  H Imamura; S Haga; T Shimizu; O Watanabe; J Kinoshita; H Nagumo; T Kajiwara; M Aiba
Journal:  Breast Cancer Res Treat       Date:  2000-08       Impact factor: 4.872

2.  Intraductal carcinoma of the breast: pathologic features associated with local recurrence in patients treated with breast-conserving therapy.

Authors:  N S Goldstein; L Kestin; F Vicini
Journal:  Am J Surg Pathol       Date:  2000-08       Impact factor: 6.394

3.  Young age is not associated with increased local recurrence for DCIS treated by breast-conserving surgery and radiation.

Authors:  Aruna Turaka; Gary M Freedman; Tianyu Li; Penny R Anderson; Ramona Swaby; Nicos Nicolaou; Lori Goldstein; Elin R Sigurdson; Richard J Bleicher
Journal:  J Surg Oncol       Date:  2009-07-01       Impact factor: 3.454

4.  Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853.

Authors:  N Bijker; J L Peterse; L Duchateau; J P Julien; I S Fentiman; C Duval; S Di Palma; J Simony-Lafontaine; I de Mascarel; M J van de Vijver
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

5.  Long term follow-up of women with ductal carcinoma in situ treated with breast-conserving surgery: the effect of age.

Authors:  K J Van Zee; L Liberman; B Samli; K N Tran; B McCormick; J A Petrek; P P Rosen; P I Borgen
Journal:  Cancer       Date:  1999-11-01       Impact factor: 6.860

6.  Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women.

Authors:  Neesha A Rodrigues; Deborah Dillon; Darryl Carter; Nicole Parisot; Bruce G Haffty
Journal:  Cancer       Date:  2003-03-15       Impact factor: 6.860

7.  Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience.

Authors:  B Fisher; S Land; E Mamounas; J Dignam; E R Fisher; N Wolmark
Journal:  Semin Oncol       Date:  2001-08       Impact factor: 4.929

8.  Differences in the pathologic features of ductal carcinoma in situ of the breast based on patient age.

Authors:  N S Goldstein; F A Vicini; L L Kestin; M Thomas
Journal:  Cancer       Date:  2000-06-01       Impact factor: 6.860

9.  Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial.

Authors:  Joan Houghton; W D George; Jack Cuzick; Catherine Duggan; Ian S Fentiman; Margaret Spittle
Journal:  Lancet       Date:  2003-07-12       Impact factor: 79.321

10.  Breast-conserving therapy for ductal carcinoma in situ of the breast: the French Cancer Centers' experience.

Authors:  Bruno Cutuli; Christine Cohen-Solal-le Nir; Brigitte de Lafontan; Hervé Mignotte; Virginie Fichet; Renaud Fay; Véronique Servent; Sylvia Giard; Claire Charra-Brunaud; Claire Lemanski; Hugues Auvray; Stéphane Jacquot; Jean-Christophe Charpentier
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-07-15       Impact factor: 7.038

View more
  5 in total

1.  Clinicopathological features and prognosis of pregnancy associated breast cancer - a matched case control study.

Authors:  Lilla Madaras; Kristóf Attila Kovács; Attila Marcell Szász; István Kenessey; Anna-Mária Tőkés; Borbála Székely; Zsuzsanna Baranyák; Orsolya Kiss; Magdolna Dank; Janina Kulka
Journal:  Pathol Oncol Res       Date:  2013-12-20       Impact factor: 3.201

2.  Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ.

Authors:  Laura C Collins; Ninah Achacoso; Reina Haque; Larissa Nekhlyudov; Suzanne W Fletcher; Charles P Quesenberry; Stuart J Schnitt; Laurel A Habel
Journal:  Breast Cancer Res Treat       Date:  2013-04-27       Impact factor: 4.872

3.  Increased SIAH expression predicts ductal carcinoma in situ (DCIS) progression to invasive carcinoma.

Authors:  Kathryn C Behling; Amy Tang; Boris Freydin; Inna Chervoneva; Sameep Kadakia; Gordon F Schwartz; Hallgeir Rui; Agnieszka K Witkiewicz
Journal:  Breast Cancer Res Treat       Date:  2010-11-19       Impact factor: 4.872

4.  Clinicopathologic Features, Treatment Patterns, and Disease Outcomes in a Modern, Prospective Cohort of Young Women Diagnosed with Ductal Carcinoma In Situ.

Authors:  Megan E Tesch; Shoshana M Rosenberg; Laura C Collins; Julia S Wong; Laura Dominici; Kathryn J Ruddy; Rulla Tamimi; Lidia Schapira; Virginia F Borges; Ellen Warner; Steven E Come; Ann H Partridge
Journal:  Ann Surg Oncol       Date:  2022-08-12       Impact factor: 4.339

5.  A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone.

Authors:  Eileen Rakovitch; Sharon Nofech-Mozes; Wedad Hanna; Frederick L Baehner; Refik Saskin; Steven M Butler; Alan Tuck; Sandip Sengupta; Leela Elavathil; Prashant A Jani; Michel Bonin; Martin C Chang; Susan J Robertson; Elzbieta Slodkowska; Cindy Fong; Joseph M Anderson; Farid Jamshidian; Dave P Miller; Diana B Cherbavaz; Steven Shak; Lawrence Paszat
Journal:  Breast Cancer Res Treat       Date:  2015-06-29       Impact factor: 4.872

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.